Mbq Pharma
MBQ-Pharma targets Rac and CDC42 as key targets for tumor growth inhibition and removal of pre-existing metastasis. MBQ-167 is a first-in-class nanomolar IC50 inhibitor for Rac and CDC42 and has been shown in mouse tumor models to inhibit tumor growth and to reverse advanced metastasis. MBQ-167 has also been shown to have no toxicity findings in rats and dogs through GLP studies and in Safety Pharmacology studies. The IND for MBQ-167 is scheduled by the end of 2021.
7-day free trial · no credit card
Verified contacts
2
available on Kipplo
LinkedIn employees
4
1 to 10 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 2 verified contacts at Mbq Pharma
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
2 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at Mbq Pharma
2 distinct titles indexed · top 2 shown.
- 1chief executive officer
- 1chief financial officer
Sign up to unlock all 2 contacts at Mbq Pharma
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 2 verified contacts at Mbq Pharma
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.